Phase 3 trial data for Eli Lilly's retatrutide — a triple agonist targeting GIP, GLP-1, and glucagon receptors - showed roughly 50% of participants losing 30% or more of their body weight. That figure approaches outcomes historically associated with gastric bypass surgery, not a once-weekly injectable.
Why it matters
The primary endpoint: sustained ≥30% body weight reduction at 48 weeks in a broadly eligible adult population — achieved at a rate no approved obesity drug has hit. Payers, bariatric surgery centers, and employers with GLP-1 coverage policies all face meaningful strategic recalibration if FDA approval follows. An FDA submission is estimated roughly 12 months out.
- ~50% of patients achieved ≥30% body weight loss (vs. ~15–22% for semaglutide)
- Triple mechanism: GIP + GLP-1 + glucagon receptor agonism
- FDA submission anticipated mid-to-late 2027; accelerated pathway possible
- Bariatric surgery average weight loss: 25–35% — retatrutide enters that range
The other side
Longer-term safety data - particularly cardiovascular events, bone density, and muscle mass retention - remains incomplete. Obesity medicine specialists caution that efficacy headlines don't yet address what happens when patients discontinue, a known Achilles' heel for the entire GLP-1 drug class.
Watch: Full Phase 3 data publication; Lilly NDA filing timeline; CMS GLP-1 coverage expansion framework for Medicare (already underway for Wegovy).